Axsome Therapeutics (NASDAQ:AXSM) CFO Nick Pizzie Sells 12,000 Shares

Axsome Therapeutics, Inc. (NASDAQ:AXSM) CFO Nick Pizzie sold 12,000 shares of the company’s stock in a transaction that occurred on Thursday, January 22nd. The shares were sold at an average price of $187.92, for a total value of $2,255,040.00. Following the completion of the sale, the chief financial officer owned 42,588 shares of the company’s stock, valued at $8,003,136.96. This trade represents a 21.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Axsome Therapeutics Price Performance

NASDAQ:AXSM opened at $185.96 on Friday. Axsome Therapeutics, Inc. has a one year low of $86.99 and a one year high of $191.50. The stock has a market cap of $9.37 billion, a PE ratio of -39.82, a P/E/G ratio of 9.86 and a beta of 0.44. The company has a debt-to-equity ratio of 1.66, a quick ratio of 1.50 and a current ratio of 1.57. The stock has a 50 day moving average price of $159.39 and a 200 day moving average price of $133.10.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.82) by ($0.12). The company had revenue of $170.99 million for the quarter, compared to analyst estimates of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.Axsome Therapeutics’s quarterly revenue was up 63.2% compared to the same quarter last year. Equities research analysts expect that Axsome Therapeutics, Inc. will post -2.79 EPS for the current fiscal year.

Key Axsome Therapeutics News

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Morgan Stanley downgraded shares of Axsome Therapeutics from an “overweight” rating to a “reduce” rating in a research note on Thursday, January 8th. Guggenheim restated a “buy” rating and set a $205.00 price target on shares of Axsome Therapeutics in a report on Friday, January 2nd. B. Riley initiated coverage on shares of Axsome Therapeutics in a research report on Wednesday, October 1st. They set a “buy” rating and a $179.00 price target on the stock. Piper Sandler upped their price objective on Axsome Therapeutics from $148.00 to $223.00 and gave the company an “overweight” rating in a report on Friday, January 16th. Finally, Wells Fargo & Company increased their price objective on Axsome Therapeutics from $157.00 to $193.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 13th. Nineteen equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, Axsome Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $203.17.

Hedge Funds Weigh In On Axsome Therapeutics

Several large investors have recently made changes to their positions in AXSM. Vanguard Group Inc. boosted its position in shares of Axsome Therapeutics by 6.0% during the 3rd quarter. Vanguard Group Inc. now owns 4,180,646 shares of the company’s stock worth $507,739,000 after purchasing an additional 235,626 shares during the period. Wellington Management Group LLP lifted its stake in Axsome Therapeutics by 84.1% during the third quarter. Wellington Management Group LLP now owns 1,334,560 shares of the company’s stock worth $162,082,000 after purchasing an additional 609,516 shares in the last quarter. Invesco Ltd. boosted its position in shares of Axsome Therapeutics by 73.3% during the third quarter. Invesco Ltd. now owns 990,557 shares of the company’s stock worth $120,303,000 after buying an additional 419,008 shares during the period. Geode Capital Management LLC grew its stake in shares of Axsome Therapeutics by 5.8% in the second quarter. Geode Capital Management LLC now owns 989,453 shares of the company’s stock valued at $103,303,000 after buying an additional 54,600 shares in the last quarter. Finally, State Street Corp grew its stake in shares of Axsome Therapeutics by 5.8% in the second quarter. State Street Corp now owns 958,503 shares of the company’s stock valued at $100,058,000 after buying an additional 52,483 shares in the last quarter. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.